Zepbound is a prescription injection containing tirzepatide, and in the United States it is approved for two things: long-term weight management in adults and moderate to severe obstructive sleep apnea in adults with obesity. You inject it once a week under the skin, alongside a reduced-calorie diet and more physical activity.
It holds the same active ingredient as Mounjaro, sold under a different brand name for a different approved use. Doses run from 2.5 mg to 15 mg once weekly, and nobody starts at the top.
What is Zepbound used for?
The weight-management approval covers adults with a body mass index of 30 or higher, and adults with a BMI of 27 or higher who also have at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. The sleep apnea approval is narrower: adults with obesity who have moderate to severe obstructive sleep apnea.
Both uses assume food and activity changes travel with the medicine. Asking what is Zepbound used for also means knowing where the label stops.
- Approved: chronic weight management in adults who meet the BMI criteria
- Approved: moderate to severe obstructive sleep apnea in adults with obesity
- Not approved: blood sugar control in type 2 diabetes, which is the Mounjaro label
- Not intended: use with another tirzepatide product or another GLP-1 medicine
- Not studied for approval in people under 18, and not for cosmetic weight loss
Because the criteria lean on BMI, it is worth knowing your number before the first appointment rather than guessing at it.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
How does Zepbound make you lose weight?
Tirzepatide copies two gut hormones at once. It activates the GLP-1 receptor and the GIP receptor, both of which are incretin hormones your body releases after eating. The result is less hunger, earlier fullness, slower stomach emptying and steadier insulin release when blood sugar rises.
Most people describe it as food noise going quiet. Portions shrink because appetite shrinks, not because the drug burns calories. That distinction matters for expectations: this is an appetite and metabolism medicine, not a fat burner or a stimulant.
Why it matters: the effect lasts while the drug is in your system, so obesity is treated here as a long-term condition rather than a short course.
Is Zepbound the same as Ozempic, Wegovy or Mounjaro?
No. Zepbound and Mounjaro share the molecule tirzepatide. Ozempic and Wegovy share a different molecule, semaglutide, which acts on the GLP-1 receptor only. Same drug class family, different ingredients and different approved uses.
Tirzepatide vs Semaglutide Brands
| Tirzepatide (Zepbound / Mounjaro) | Semaglutide (Wegovy / Ozempic) | |
|---|---|---|
| Receptor action | GIP + GLP-1 | GLP-1 only |
| Weight management approval | Zepbound | Wegovy |
| Type 2 diabetes approval | Mounjaro | Ozempic |
| Sleep apnea approval | Zepbound | None |
| Brand | Active ingredient | Receptor action | Main approved use |
|---|---|---|---|
| Zepbound | Tirzepatide | GIP and GLP-1 | Weight management; obstructive sleep apnea with obesity |
| Mounjaro | Tirzepatide | GIP and GLP-1 | Type 2 diabetes |
| Wegovy | Semaglutide | GLP-1 | Weight management; cardiovascular risk reduction |
| Ozempic | Semaglutide | GLP-1 | Type 2 diabetes |
People search for an Ozempic to Zepbound conversion chart, but no official one exists. The milligram numbers are not comparable between semaglutide and tirzepatide, so a clinician switching you over normally restarts near the bottom of the tirzepatide ladder and steps up again. Ask what the plan is before the switch, not after the first injection.
Zepbound dosage and the weekly routine
Treatment starts at 2.5 mg once weekly for four weeks. That first month is a tolerance step, not a treatment dose. After it, the usual move is up to 5 mg weekly, with further increases of 2.5 mg allowed after at least four weeks at the current dose. Maintenance doses are 5 mg, 10 mg or 15 mg, and 15 mg once weekly is the maximum.
The medicine comes as single-dose injections you give yourself in the stomach, thigh or upper arm, rotating the site each week. Pick one day a week and keep it. If you miss a dose, the label allows you to take it within four days; after that, skip it and inject on your next scheduled day.
- One injection per week, with or without food
- Never double up to make up a missed week
- Dose changes wait at least four weeks, so escalation is slow by design
- Tell your clinician if side effects are stopping you from eating or drinking normally
How much does Zepbound cost without insurance?
Cash prices move with the pharmacy, the dose and the channel. Here is the current spread across the providers we track for tirzepatide: $99 to $399
Four things push your number up or down: whether you get single-dose pens or vials, which dose you are on, how many weeks you buy at once, and whether the quoted figure includes a consultation or membership fee. The manufacturer also runs a direct self-pay route for vials, which is priced separately from retail pharmacy counters. Compounded tirzepatide is a different matter: it is not the FDA-approved product, and federal restrictions on compounding tightened once the shortage ended.
No provider matches that filter. .
See every provider we track, with filters and sorting
Since this is a long-term medicine, the monthly figure matters less than the yearly one. Run your own number rather than trusting a headline price.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Is Zepbound covered by insurance?
Sometimes, and the mechanics decide it. Many commercial plans cover it only after prior authorization, which means documented BMI, a weight-related condition, and often proof you tried lifestyle programs. Step therapy can require a cheaper GLP-1 first. Some employers carve out weight-loss drugs from the plan entirely, in which case no appeal will help because the benefit does not exist.
- Prior authorization: your prescriber submits BMI, diagnoses and prior attempts
- Step therapy: the plan may want a preferred alternative tried first
- Coinsurance vs copay: a percentage of a high-cost drug hurts far more than a flat copay
- Deductible phase: early in the plan year you may pay the full negotiated rate
- Manufacturer savings card: usually limited to commercially insured patients, never Medicare or Medicaid
Medicare Part D has long excluded drugs used for weight loss by statute, which is why the sleep apnea indication changed the conversation: a plan may cover the drug for a covered medical use even when weight loss alone is excluded. Medicaid coverage varies state by state. If a denial arrives, ask for the written reason and the appeal deadline, then have your clinician file with clinical notes attached.
No provider matches that filter. .
See every provider we track, with filters and sorting
What the trials and the reviews actually show
In the 72 week SURMOUNT-1 trial of adults with obesity and without diabetes, average weight loss was 15 percent at 5 mg, 19.5 percent at 10 mg and 20.9 percent at 15 mg (New England Journal of Medicine). Those are averages over 18 months at maintenance doses, not first-month results.
First-month reviews read differently for that reason. Month one is the 2.5 mg starter dose, and a few pounds is a normal outcome. Appetite change often arrives before the scale moves much. Progress also comes in steps rather than a straight line, because each dose increase tends to restart the effect.
The critical reviews cluster around three themes, and all three are worth planning for: stomach side effects during escalation, the cost of staying on it, and weight returning after stopping. Trial data on withdrawal supports that last point, which is why clinicians treat this as ongoing therapy rather than a finite course.
Side effects, boxed warning and who should not take it
The common side effects are mostly digestive: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, burping, tiredness, hair thinning and reactions where you inject. They are usually worst in the days after a dose increase and settle as your body adjusts.
Zepbound carries a boxed warning for thyroid C-cell tumors seen in rodent studies, and the human relevance is not established (FDA approval announcement). Do not use it if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2, or a serious allergic reaction to tirzepatide.
- Pancreatitis: severe, persistent stomach pain that may spread to your back needs urgent care
- Gallbladder problems: right-sided pain, fever, yellow skin or clay-colored stools
- Low blood sugar: risk rises if you also take insulin or a sulfonylurea, so doses of those may need review
- Dehydration and kidney injury: heavy vomiting or diarrhea can damage kidney function
- Mood changes: report new depression or thoughts of self-harm
- Vision: people with type 2 diabetes and retinopathy need eye monitoring
- Surgery and sedation: tell the anesthesia team you take it, because delayed stomach emptying raises aspiration risk
Two practical interactions get missed. Oral hormonal contraceptives can become less effective, so the label advises a non-oral method or an added barrier method for four weeks after starting and after each dose increase. And because the stomach empties more slowly, timing of other oral medicines is worth reviewing with a pharmacist. Zepbound is not recommended in pregnancy.
Storage, handling and travel
Keep it in the refrigerator at 2 to 8 degrees Celsius, which is 36 to 46 degrees Fahrenheit. Do not freeze it, and do not use it if it has frozen. Unopened injections can sit at room temperature up to 30 degrees Celsius, 86 degrees Fahrenheit, for up to 21 days, then must be used or discarded.
Check the liquid before injecting: it should be clear and colorless to slightly yellow, with no particles. Used needles and pens go in a sharps container, never household trash. For flights, carry it in hand luggage with a cool pack, since cargo holds swing outside the safe range.
Zepbound for sleep apnea: what that approval means
Zepbound became the first drug approved in the United States for moderate to severe obstructive sleep apnea in adults with obesity, based on trials measuring breathing interruptions per hour of sleep alongside weight change (FDA sleep apnea approval). It is used with a reduced-calorie diet and more activity, as with the weight indication.
It is not a straight swap for CPAP. Some people used both in the trials, and stopping a CPAP machine is a clinical decision that usually follows a repeat sleep study. If you are being treated for sleep apnea, ask whether your diagnosis is documented as moderate to severe, since that phrasing is what a coverage review looks for.
What to ask before you start
- Do I meet the labeled BMI criteria, and is my weight-related condition documented in the chart?
- Does my plan cover this, and if it needs prior authorization, who files it and when?
- What is my total monthly cost at the maintenance dose, including any consultation fee?
- Which of my current medicines need adjusting, especially insulin, sulfonylureas or oral contraceptives?
- How will we handle nausea during escalation, and at what point do we pause a dose increase?
- What happens if I stop, and what does the long-term plan look like?
If cost is the deciding factor, weigh the cash figure against what the service actually includes: clinician access, dose adjustments, refill handling and support between visits.
Best on value
What you get for what you pay.
- Found8.9 / 10
- LillyDirect8.5 / 10
- ShedRx8.2 / 10
- Henry Meds8.2 / 10
- Lumimeds8 / 10
Lowest monthly price
Cheapest verified plan for a new self-pay patient.
- Amazon One Medical$17/mo
- LifeMD$19/mo
- PlushCare$20/mo
- Hims$22/mo
- Strut Health$25/mo
Ranked from our own scores, recomputed as data changes. Providers cannot pay for a place.
Authoritative sources
- FDA announcement of approval for chronic weight management
- FDA announcement of the obstructive sleep apnea approval
- Peer-reviewed SURMOUNT-1 trial report
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
